Tarsus Pharmaceuticals (TARS) director details options, RSUs and trust shares

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director David E. I. Pyott filed an initial statement of beneficial ownership, reporting his equity holdings in the company. The filing lists several stock options granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan that vested and became exercisable on April 24, 2023, August 1, 2024, and April 24, 2025. Another option grant is scheduled to vest and become exercisable on April 24, 2026, subject to his continuous service. He also holds restricted stock units that vest on April 24, 2026, subject to continuous service. In addition, 7,991 shares of common stock are reported as held indirectly by the David E.I. Pyott Trust.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

PYOTT DAVID E I

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/18/2026

3. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,991	I	By the David E.I. Pyott Trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	06/19/2032	Common Stock	7,000	$12.97	D
Stock Option (right to buy)	(2)	07/31/2033	Common Stock	2,500	$18.27	D
Stock Option (right to buy)	(3)	04/23/2034	Common Stock	2,500	$32.76	D
Stock Option (right to buy)	(4)	04/23/2035	Common Stock	2,128	$49.97	D
Restricted Stock Units	(5)	(5)	Common Stock	1,383	$0	D

Explanation of Responses:

1. Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan (the "Plan"). The option shares vested and became exercisable on April 24, 2023.

2. Option granted under the Plan. The option shares vested and became exercisable on August 1, 2024.

3. Option granted under the Plan. The option shares vested and became exercisable on April 24, 2025.

4. Option granted under the Plan. The option shares vest and become exercisable on April 24, 2026, subject to the Reporting Person's continuous service.

5. Restricted Stock Units ("RSUs") granted under the Plan. The RSUs vest on April 24, 2026, subject to the Reporting Person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Scott Sieckert, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does David E. I. Pyott’s Form 3 disclose for Tarsus (TARS)?

The Form 3 discloses David E. I. Pyott’s initial equity holdings in Tarsus Pharmaceuticals, including stock options, restricted stock units, and common shares held indirectly through the David E.I. Pyott Trust as of the reported date.

How many Tarsus (TARS) common shares does the David E.I. Pyott Trust hold?

The filing reports that 7,991 shares of Tarsus Pharmaceuticals common stock are held indirectly by the David E.I. Pyott Trust, reflecting Pyott’s indirect ownership position separate from his stock options and restricted stock units.

What stock options does David E. I. Pyott report in his Tarsus (TARS) Form 3?

He reports several stock option awards under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, with option shares that vested on April 24, 2023, August 1, 2024, and April 24, 2025, plus an additional option scheduled to vest on April 24, 2026.

When do David E. I. Pyott’s restricted stock units in Tarsus (TARS) vest?

The restricted stock units reported in the Form 3 were granted under the Tarsus 2020 Stock Plan and are scheduled to vest on April 24, 2026, provided that David E. I. Pyott maintains continuous service with the company through that date.

Does this Tarsus (TARS) Form 3 show any insider stock purchases or sales?

No, the Form 3 does not show any insider purchases or sales. It is an initial statement of beneficial ownership listing existing holdings, with all transactions categorized as holdings and no buy or sell transactions reported.

What role does David E. I. Pyott hold at Tarsus (TARS) according to the Form 3?

According to the filing, David E. I. Pyott is a director of Tarsus Pharmaceuticals. The Form 3 outlines his beneficial ownership in company equity, including options, restricted stock units, and indirectly held common shares through a trust.